Kim Y - Search Results

1

Efficacy of newly discovered DNA aptamers targeting AXL in a lung cancer cell with acquired resistance to Erlotinib.

Hwang JA, Hur JY, Kim Y, Im JH, Jin SH, Ryu SH, Choi CM. Hwang JA, et al. Among authors: kim y. Transl Cancer Res. 2021 Feb;10(2):1025-1033. doi: 10.21037/tcr-20-2447. Transl Cancer Res. 2021. PMID: 35116429 Free PMC article.

2

Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer.

Jung YJ, Oh IJ, Kim Y, Jung JH, Seok M, Lee W, Park CK, Lim JH, Kim YC, Kim WS, Choi CM. Jung YJ, et al. Among authors: kim yc, kim y, kim ws. J Korean Med Sci. 2018 Dec 13;33(53):e342. doi: 10.3346/jkms.2018.33.e342. eCollection 2018 Dec 31. J Korean Med Sci. 2018. PMID: 30595683 Free PMC article.

3

The synthetic chemoattractant peptide, Trp-Lys-Tyr-Met-Val-D-Met, enhances monocyte survival via PKC-dependent Akt activation.

Bae YS, Kim Y, Park JC, Suh PG, Ryu SH. Bae YS, et al. Among authors: kim y. J Leukoc Biol. 2002 Feb;71(2):329-38. J Leukoc Biol. 2002. PMID: 11818455

4

Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis.

Lee YJ, Kim IS, Park SA, Kim Y, Lee JE, Noh DY, Kim KT, Ryu SH, Suh PG. Lee YJ, et al. Among authors: kim kt, kim is, kim y. Mol Ther. 2013 May;21(5):1004-13. doi: 10.1038/mt.2013.30. Epub 2013 Mar 19. Mol Ther. 2013. PMID: 23511245 Free PMC article.

5

Mechanistic understanding of insulin receptor modulation: Implications for the development of anti-diabetic drugs.

Yunn NO, Kim J, Kim Y, Leibiger I, Berggren PO, Ryu SH. Yunn NO, et al. Among authors: kim j, kim y. Pharmacol Ther. 2018 May;185:86-98. doi: 10.1016/j.pharmthera.2017.12.005. Epub 2017 Dec 18. Pharmacol Ther. 2018. PMID: 29262294 Review.

6

An aptamer agonist of the insulin receptor acts as a positive or negative allosteric modulator, depending on its concentration.

Yunn NO, Lee J, Lee HS, Oh EJ, Park M, Park S, Jin SY, Shin E, Lee JWY, Kim Y, Bae SS, Ryu SH. Yunn NO, et al. Among authors: kim y. Exp Mol Med. 2022 Apr;54(4):531-541. doi: 10.1038/s12276-022-00760-w. Epub 2022 Apr 27. Exp Mol Med. 2022. PMID: 35478209 Free PMC article.

7

Development of a Protein Biomarker Panel to Detect Non-Small-Cell Lung Cancer in Korea.

Jung YJ, Katilius E, Ostroff RM, Kim Y, Seok M, Lee S, Jang S, Kim WS, Choi CM. Jung YJ, et al. Among authors: kim y, kim ws. Clin Lung Cancer. 2017 Mar;18(2):e99-e107. doi: 10.1016/j.cllc.2016.09.012. Epub 2016 Oct 5. Clin Lung Cancer. 2017. PMID: 27836219

8

Differential activation of formyl peptide receptor signaling by peptide ligands.

Bae YS, Song JY, Kim Y, He R, Ye RD, Kwak JY, Suh PG, Ryu SH. Bae YS, et al. Among authors: kim y. Mol Pharmacol. 2003 Oct;64(4):841-7. doi: 10.1124/mol.64.4.841. Mol Pharmacol. 2003. PMID: 14500740

9

Pituitary adenylate cyclase-activating polypeptide 27 is a functional ligand for formyl peptide receptor-like 1.

Kim Y, Lee BD, Kim O, Bae YS, Lee T, Suh PG, Ryu SH. Kim Y, et al. Among authors: kim o. J Immunol. 2006 Mar 1;176(5):2969-75. doi: 10.4049/jimmunol.176.5.2969. J Immunol. 2006. PMID: 16493055

10

Collapsin response mediator protein-2 inhibits neuronal phospholipase D(2) activity by direct interaction.

Lee S, Kim JH, Lee CS, Kim JH, Kim Y, Heo K, Ihara Y, Goshima Y, Suh PG, Ryu SH. Lee S, et al. Among authors: kim y, kim jh. J Biol Chem. 2002 Feb 22;277(8):6542-9. doi: 10.1074/jbc.M108047200. Epub 2001 Dec 10. J Biol Chem. 2002. PMID: 11741937 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86,163 results

Search Page

Filters